Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

Clinical trial NCT06882499 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06882499
Sponsor: Peter MacCallum Cancer Centre, Australia
Status: NOT_YET_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Breast Cancer, Metastatic Metastatic Breast Cancer

Start date: 2026-06-01
Primary completion: 2032-06-01
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.